查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511835

美国表观遗传学市场规模、份额、趋势分析报告：按产品、按技术、按应用、按最终用途、细分市场预测，2024-2030 年

U.S. Epigenetics Market Size, Share & Trends Analysis Report By Product (Reagents, Kits), By Technology (DNA Methylation, Histone Methylation), By Application (Oncology, Non-oncology), By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

美国表观遗传学市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，美国表观遗传学市场规模预计将达到131亿美元，2024年至2030年复合年增长率为14.5%。

癌症和慢性病盛行率的增加、表观遗传学研究和技术的进步、生物医学研究投资的增加以及个人化医疗的日益采用将增加预测期内对錶观遗传学的需求。

COVID-19 大流行对市场产生了积极影响。这场大流行促使有关了解该病毒及其对人体影响的研究活动显着增加。其中包括研究 COVID-19 如何影响基因表现和免疫反应的表观遗传学研究。因此，政府和私营部门对与 COVID-19 相关的表观遗传学研究的资助增加。

此外，企业也增加了对錶观遗传产品开发的投资。许多生物技术和製药公司增加了研发预算，以探索表观遗传学在疾病机制和治疗反应中的作用。资本的涌入正在加快该领域发现和创新的步伐。卫生系统从外部资金转向国内投资的转变凸显了对创新解决方案的需求。预计表观遗传学与医疗保健进步相结合将透过提供改善健康结果的解决方案来改变游戏规则。

然而，市场成长因缺乏熟练的专业人员而受到限制。表观遗传学的复杂性需要对遗传学、分子生物学和资料分析的深入理解。这种短缺可能会减缓研究和技术进步，阻碍对见解至关重要的复杂资料分析，延迟临床转化，并阻碍教育倡议。预计这将在一定程度上阻碍市场成长。

美国表观遗传学市场报告亮点

  • 试剂在产品领域占据主导地位，2023 年收益占有率最大，为 32.5%。试剂用途广泛，应用广泛，包括基础研究、临床诊断及药物开发。同时，服务预计在预测期内将以最快的复合年增长率成长。
  • 在技​​术领域，DNA甲基化在2023年占据最大的市场占有率。 DNA甲基化是重要的表观遗传修饰之一，在基因表现调控中扮演重要角色。但另一方面，组蛋白乙酰化预计在预测期内以最快的复合年增长率成长。
  • 从应用来看，肿瘤学在 2023 年占据最大的市场占有率。这是由于癌症盛行率不断增加。然而，另一方面，非肿瘤学预计在预测期内将以最快的复合年增长率成长。
  • 根据最终用途，学术研究在 2023 年收益占有率最大的领域占据主导地位。这是由于学术机构进行的临床研究数量不断增加以及研究活动的资金不断增加。另一方面，临床研究预计在预测期内将以最快的复合年增长率成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章美国表观遗传学市场：产品业务分析

  • 细分仪表板
  • 美国表观遗传学市场：产品变异分析
  • 2018-2030 年美国表观遗传学市场规模与趋势分析（按产品）
  • 试剂
  • 套件
  • 装置
  • 酵素
  • 服务

第五章美国表观遗传学市场：技术商业分析

  • 细分仪表板
  • 美国表观遗传学市场：技术波动分析
  • 2018-2030年美国表观遗传学合成市场规模及趋势分析（依技术）
  • DNA甲基化
  • 组蛋白甲基化
  • 组蛋白乙酰化
  • 大非编码RNA
  • 微型RNA修饰
  • 染色质结构

第六章美国表观遗传学市场：应用商业分析

  • 细分仪表板
  • 美国表观遗传学市场：应用变异分析
  • 2018-2030 年美国表观遗传学合成市场规模与趋势分析（按应用）
  • 肿瘤学
  • 非肿瘤学

第七章美国表观遗传学市场：最终用途业务分析

  • 细分仪表板
  • 美国表观遗传学市场：最终用途变异分析
  • 2018-2030 年美国表观遗传学市场规模与趋势分析（依最终用途）
  • 学术研究
  • 临床调查
  • 医院/诊所
  • 製药和生物技术公司
  • 其他的

第八章 竞争格局

  • 参与企业
  • 策略规划
  • 2023 年企业市场分析
  • 参与企业概况
    • Roche Diagnostics
    • Thermo Fisher Scientific, Inc.
    • Danaher
    • Eisai Co. Ltd.
    • Novartis AG
    • Element Biosciences, Inc.
    • Dovetail Genomics LLC.
    • Illumina, Inc.
    • Promega Corporation.
    • Abcam plc.
Product Code: GVR-4-68040-301-9

U.S. Epigenetics Market Growth & Trends:

The U.S. epigenetics market size is anticipated to reach USD 13.10 billion by 2030, growing at a CAGR of 14.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of cancer and chronic diseases, advancements in epigenetic research and technologies, rising investment in biomedical research, and increasing adoption of personalized medicine are anticipated to increase the demand for epigenetics over the forecast period.

The COVID-19 pandemic has had a positive impact on the market. The pandemic spurred a significant increase in research activities related to understanding the virus and its effects on human health. This included epigenetic research to study how COVID-19 affects gene expression and immune responses. Consequently, there was increased funding from both government and private sectors for epigenetic studies related to COVID-19.

Moreover, companies have increased investments in the development of epigenetics products. Many biotechnology and pharmaceutical companies have increased their research and development budgets to explore the role of epigenetics in disease mechanisms and treatment responses. This influx of funding has accelerated the pace of discoveries and innovations in the field. The transition from external funding to domestic investment in health systems underscores the need for innovative solutions. Epigenetics, embedded in advancing healthcare, is projected to transform the phase by offering solutions for improving health outcomes.

However, the growth of the market is constrained by a scarcity of skilled professionals. The complex nature of epigenetics demands a deep understanding of genetics, molecular biology, and data analysis. This shortage can decelerate research & technological progress, hinder complex data analysis crucial for insights, slow clinical translation, and hamper educational initiatives. This is anticipated to hamper the growth of the market to a certain extent.

U.S. Epigenetics Market Report Highlights:

  • Reagents dominated the product segment with the largest revenue share of 32.5% in 2023. Reagents are versatile and used in a wide range of applications, including basic research, clinical diagnostics, and drug development. On the other hand, services are expected to grow at the fastest CAGR over the forecast period.
  • The DNA methylation held the largest market share in 2023 for the technology segment. DNA methylation is one of the key epigenetic modifications that plays a vital role in regulating gene expression. However, on the other hand, histone acetylation is expected to grow at the fastest CAGR over the forecast period.
  • The oncology held the largest market share in 2023 for the application segment. This is attributed to the growing prevalence of cancer. However, on the other hand, non-oncology is expected to grow at the fastest CAGR over the forecast period.
  • Based on end-use, academic research dominated the segment with the largest revenue share in 2023. This is attributed to the increasing number of clinical studies which are being conducted in academic institutes and the growing funding for research activities. On the other hand, clinical research is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. End-use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Rising geriatric patient population
      • 3.2.1.3. Increasing government initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of standardization in epigenetics-based diagnostics
      • 3.2.2.2. Lack of skilled professionals
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Epigenetics Market: Product Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Epigenetics Market Product Movement Analysis
  • 4.3. U.S. Epigenetics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Reagents
    • 4.4.1. Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5. Kits
    • 4.5.1. Kits market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.2. ChIP Sequencing Kit
      • 4.5.2.1. ChIP sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.3. Whole Genomic Amplification Kit
      • 4.5.3.1. Whole genomic amplification kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.4. Bisulfite Conversion Kit
      • 4.5.4.1. Bisulfite conversion kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.5. RNA Sequencing Kit
      • 4.5.5.1. RNA sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.6. Others
      • 4.5.6.1. Others market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.6. Instruments
    • 4.6.1. Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.7. Enzymes
    • 4.7.1. Enzymes market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.8. Services
    • 4.8.1. Services market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Epigenetics Market: Technology Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Epigenetics Market Technology Movement Analysis
  • 5.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 5.4. DNA Methylation
    • 5.4.1. DNA methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. Histone Methylation
    • 5.5.1. Histone methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Histone Acetylation
    • 5.6.1. Histone acetylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. Large Non - coding RNA
    • 5.7.1. Large non - coding RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.8. MicroRNA Modification
    • 5.8.1. MicroRNA modification market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.9. Chromatin Structures
    • 5.9.1. Chromatin structures market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Epigenetics Market: Application Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Epigenetics Market Application Movement Analysis
  • 6.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.2. Solid Tumors
      • 6.4.2.1. Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.3. Liquid Tumors
      • 6.4.3.1. Liquid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5. Non-oncology
    • 6.5.1. Non-oncology market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.2. Inflammatory Diseases
      • 6.5.2.1. Inflammatory diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.3. Metabolic Diseases
      • 6.5.3.1. Metabolic diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.4. Infectious Diseases
      • 6.5.4.1. Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.5. Cardiovascular Diseases
      • 6.5.5.1. Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.6. Others
      • 6.5.6.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. U.S. Epigenetics Market: End-use Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Epigenetics Market End-use Movement Analysis
  • 7.3. U.S. Epigenetics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 7.4. Academic Research
    • 7.4.1. Academic research market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Clinical Research
    • 7.5.1. Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6. Hospitals & Clinics
    • 7.6.1. Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7. Pharmaceutical & Biotechnology Companies
    • 7.7.1. Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8. Others
    • 7.8.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Participant's Overview
    • 8.4.1. Roche Diagnostics
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product & service benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Thermo Fisher Scientific, Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product & service benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Danaher
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product & service benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Eisai Co. Ltd.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product & service benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product & service benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Element Biosciences, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product & service benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Dovetail Genomics LLC.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product & service benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Illumina, Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product & service benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Promega Corporation.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product & service benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Abcam plc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product & service benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. epigenetics market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. epigenetics market, by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S. epigenetics market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. epigenetics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Participant's overview
  • Table 8 Financial performance
  • Table 9 Key companies undergoing expansions
  • Table 10 Key companies undergoing acquisitions
  • Table 11 Key companies undergoing collaborations
  • Table 12 Key companies launching new products/services
  • Table 13 Key companies undertaking other strategies

List of Figures

  • Fig. 1 U.S. epigenetics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 U.S. epigenetics market driver analysis
  • Fig. 14 U.S. epigenetics market restraint analysis
  • Fig. 15 U.S. epigenetics market: Porter's analysis
  • Fig. 16 U.S. epigenetics market: Product outlook key takeaways
  • Fig. 17 U.S. epigenetics market: Product movement analysis
  • Fig. 18 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Kits market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 ChIP sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Whole genomic amplification kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Bisulfite conversion kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 RNA sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. epigenetics market: Technology movement analysis
  • Fig. 26 U.S. epigenetics market: Technology outlook and key takeaways
  • Fig. 27 DNA methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Histone methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Histone acetylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Large non - coding RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 MicroRNA modification market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Chromatin structures market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. epigenetics market: Application movement analysis
  • Fig. 34 U.S. epigenetics market: Application outlook and key takeaways
  • Fig. 35 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Liquid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Non-oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Inflammatory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Metabolic diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. epigenetics market End-use outlook key takeaways
  • Fig. 45 U.S. epigenetics market: End-use movement analysis
  • Fig. 46 Academic research market estimates and forecast, 2018 - 2030 (USD Million))
  • Fig. 47 Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Key company categorization
  • Fig. 52 Company market positioning
  • Fig. 53 Market participant categorization
  • Fig. 54 Strategy framework